A pharmacy-based protocol for naloxone distribution and training

Community pharmacists are often the health professional a person can reach quickly when an opioid emergency is unfolding or when a household wants to prepare. A pharmacy-based protocol for naloxone distribution and training turns that access into a reliable service: defined eligibility, stocked products, trained staff, clear referral pathways and a repeatable client experience. It also recognises naloxone as a safety tool rather than a clinical substitute for emergency care.

A workable Australian protocol must fit a patchwork of state and territory rules, public funding and local pharmacy arrangements. It should make it easy for a client or bystander to obtain take-home naloxone, explain when to call 000, and support safe administration without demanding unnecessary proof, a Medicare card or disclosure of sensitive information. The result should be usable by independent chemists, hospital pharmacy teams, Aboriginal health services and regional pharmacists.

Why pharmacy access must be predictable

Opioid overdose can affect people who inject drugs, people prescribed strong opioids for pain, and those exposed to illicitly manufactured substances of unknown strength. Naloxone reverses opioid-induced respiratory depression, but it is effective only when it reaches the person quickly. Community pharmacies can shorten that interval by supplying take-home doses, training relatives and friends, and connecting clients with treatment and other support.

Access differs considerably across Australia. In New South Wales, including metropolitan Sydney and regional areas, the Naloxone Access Program supports free take-home naloxone through participating pharmacies. The ACT provides access through a standing-order model, with free naloxone available from participating pharmacies without requiring a Medicare card. Western Australia’s My Choice program likewise offers free naloxone through participating pharmacies and other local services. A national approach therefore needs a consistent service standard while allowing each jurisdiction to determine the legal supply mechanism.

The protocol should identify a responsible clinical lead, participating locations, eligible products and stock levels. It should also define what staff do when a person has no prescription, cannot afford the medicine or needs several doses for a household. Naloxone must be presented as a practical harm-reduction measure, with emergency care, treatment referral and respectful communication built into every encounter.

Governance, law and product safety

Naloxone is a Schedule 4 Prescription Only Medicine, and Australian rules for supply without a prescription vary between states and territories. Depending on the jurisdiction, supply may rely on emergency supply provisions, a standing order, delegated authority or another approved arrangement. Each participating pharmacy should document the legal basis, authorised staff, required records and clinical escalation pathway in accordance with the relevant pharmacy board or council requirements.

Product governance is equally important. Approved naloxone formulations appear on the Australian Register of Therapeutic Goods, administered by the Therapeutic Goods Administration, and purchasing should be based on current regulatory status rather than an old price list or informal recommendation. For non-injectable formats, product-specific claims such as buccal naloxone information should be checked against the current ARTG listing, approved indications and instructions. Stock records should capture batch numbers, expiry dates and storage requirements.

The protocol needs a process for reporting adverse reactions, product defects, near misses and unsuccessful reversals without blaming the person receiving care. The TGA and relevant state pharmacy authority may need notification, while internal review should focus on correct product selection, dose escalation, referral quality and system failures. Privacy obligations, including the Privacy Act 1988 and the Pharmacy Board of Australia’s privacy and confidentiality requirements, should be reflected in recordkeeping and staff training.

A practical supply pathway

Every pharmacy should follow a short, consistent pathway from the first conversation to safe take-home use. Staff should ask what the person is seeking, assess whether an opioid exposure or overdose risk is present, confirm any legal requirements for supply, and provide naloxone without unnecessary questioning. Where local legislation permits, the pathway should allow supply to a person at risk or to a nominated family member or bystander.

The client should receive the appropriate device or ampoule, an emergency instruction card and a demonstration that is appropriate to their experience. Staff must explain that 000 should be called, rescue breathing and cardiopulmonary resuscitation should begin when indicated, and further naloxone may be needed at the interval specified by the product instructions and local clinical guideline. Nobody should be left alone, and naloxone should never be presented as a reason to delay ambulance attendance.

Medication review should occur whenever practical. Opioids may be combined with benzodiazepines, alcohol, gabapentinoids or other sedatives, increasing the likelihood of respiratory depression. The medication-review discipline described in a benzodiazepine deprescribing framework can support careful conversations about sedatives without creating abrupt withdrawal or another source of harm. Where appropriate, pharmacy staff should also refer the person to their prescriber, an opioid treatment program, an alcohol and other drug service or a local harm-reduction service.

Training that changes clinical practice

Training should cover opioid overdose recognition, naloxone pharmacology, rescue breathing, cardiopulmonary resuscitation, emergency communication and safe sharps disposal. Staff also need to understand why naloxone may require repeated administration and why it does not reverse non-opioid causes of unconsciousness. Training must be tailored for dispensary staff, pharmacists, front-of-shop team members and relief personnel who may be the first person a client encounters.

Short role-plays are valuable because they reveal whether staff can speak calmly, ask direct questions and correct unsafe misconceptions. Participants should practise responding to “What if I use the wrong dose?”, “Do I need a prescription?”, and “Can I give this to my partner?” Scenarios involving a person who has lost consciousness, a distressed family member or a client from a different cultural background help prepare staff for situations that standard written guidance may not capture.

Competency should be documented through observation, a knowledge check and supervised practice. New staff should complete training before joining the service, while existing staff need scheduled refreshers and updates when laws, products or referral arrangements change. External trainers can support larger networks, but local clinical leaders should remain responsible for reviewing incidents and ensuring that learning is applied consistently.

A respectful client-centred service

Stigma can prevent people from seeking help or accepting naloxone. Training should ask staff to examine assumptions, use neutral language and focus on safety without implying that a person has behaved irresponsibly. Published advice on supportive pharmacy environments reinforces the value of a welcoming counter, confidential counselling and non-judgmental follow-up. The same principles apply when a client discloses distress, fear of overdose or concern that someone else may die.

Local service design matters. Pharmacies near Melbourne’s North Melbourne supervised injecting room can provide take-home supplies, treatment information and a route back into care without requiring clients to enter the facility. In regional and remote areas, stock availability, pharmacist workload and transport distances may determine whether someone can obtain naloxone in time. Partnerships with Needle and Syringe Programs, Aboriginal Community Controlled Health Services, opioid treatment clinics and alcohol and other drug services can extend reach where pharmacies are scarce.

Culturally safe care should be planned with local communities rather than delivered as a generic message. Aboriginal and Torres Strait Islander clients may prefer to receive information through an Aboriginal health worker or community-controlled service. Written instructions should be available in commonly used community languages, and staff should use a qualified interpreter when needed. Supplying naloxone to a trusted family member or support person can also improve response times, provided privacy and consent are respected.

Monitoring outcomes and improving the program

Evaluation should include more than the number of packs distributed. Useful measures include the proportion of participating pharmacies stocking each approved formulation, staff training completion, access without a prescription where permitted, referral completion and the time taken to replace naloxone after use. Stock-out reasons should be recorded so that forecasting can reflect local demand rather than a single national average.

Equity measures should examine access in regional and remote locations, access without Medicare or identification, and the availability of culturally and linguistically appropriate support. Data collection should remain proportionate. If a client declines identification or follow-up, the service should still provide immediate assistance without making care conditional on consent to additional information sharing.

A quarterly review can bring together pharmacists, the clinical lead, jurisdictional program managers and people with lived experience. Reviewers should examine complaints, near misses, clinical outcomes and consumer feedback, then document actions and responsibilities. Expansion should proceed only after the pathway is safe, funded and understood by frontline staff; sustainability depends on reliable wholesale pricing, predictable government or program funding and continuing training rather than unpaid goodwill alone.

Pharmacy leaders can begin by appointing a naloxone service lead, confirming the supply rules in their jurisdiction and identifying a reliable wholesaler. They can then equip every participating location with approved products, emergency instructions and a referral directory, while training all staff in realistic scenarios.

Adopt the protocol, test it with local partners and make take-home naloxone an ordinary, accessible part of every participating Australian community pharmacy.